Phaseline

Companies › Atom Therapeutics

Atom Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine, Cardiovascular, Immunology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABP-671–Phase 2Chronic Kidney Disease; Gout ChronicOct 2027
ABP-745–Phase 2Acute Gouty Arthritis; Atherosclerosis Cardiovascular DiseaseJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07145229ABP-745Phase 2Acute Gouty ArthritisImmunologyJul 2026
NCT07367971ABP-671Phase 1Gout ChronicMetabolic and endocrineAug 2026
NCT07323095ABP-671Phase 2Chronic Kidney DiseaseGenitourinaryOct 2027
NCT07303777ABP-745Phase 2Atherosclerosis Cardiovascular DiseaseCardiovascularJan 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vincentage Pharma Rege Nephro Vifor Pharma Sparrow Pharmaceuticals Sirius Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.